预约演示
Pelage secures funds to develop regenerative medicine for hair loss
临床1期临床结果
Affecting both men and women, androgenetic alopecia or pattern balding is responsible for more than 90% of all hair loss. Credit: zentradyi3ell / Shutterstock.com.
Pelage Pharmaceuticals has secandrogenetic alopeciaies pattern baldingnd to further the development of PP405, ahair lossg regenerative treatment for hair loss caused by androgenetic alopecia.
Pelage Pharmaceuticalsnd, with Main Street Advisors, Visionary Ventures and YK BioVentures also taking PP405hair lossandrogenetic alopecia
The capital injection will be instrumental in advanciVisionary VentureslinicYK BioVentures
A non-invasive, topical small molecule, PP405 reactivatePP405mant hair follicle stem cells and stimulates hair regrowth.
By targeting the metabolic processes thaPP405ulate hair follicle stem cells’ activation and inactivation phases, the treatment adopts a regenerative medicine approach to combat alopecia, including forms induced by chemotherapy.
See Also:Novo Nordisk signs $1.46bn deal to develop molecular glue therapiesalopecia
Praxis PrNovo Nordiskcines sees highest patent filings and grants during November in Q4 2023
PP405 was well-tolerated in a Phase I clinical trial and significantly activated hair follicle stem cells.
Praxis Precision Medicinestment administered daily was found to be safe without adverse events. This data confirms the treatment’s biological activity and mechanism of action observed in preclinical studies.
The intellectual property rights for PP405 and related topical small molecules were acquired by Pelage Pharmaceuticals from the UCLA Technology Development Group in 2018.
PP405e Pharmaceuticals CEO Daniel Gil stated: “We are pleased to announce that we have completed a first-in-human Phase I clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells.
“With thPP405port of GV, Main Street Advisors and other top-tier investors, we expect to advance our lead programme to a Phase IIa clinical trial in the second half of this year.”
Affecting both men and women, androgePP405 alopecia or pattern balding is responsible for more tPelage Pharmaceuticalsss.UCLA Technology Development Group
Pelage Pharmaceuticalsc alopecia, the company anticipates that PP405 has applications for other hair loss types, including stress-induced hair loss or telogen effluvium and chemotherapy-induced hair loss.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。